Compare Morgan Stanley (MS) vs Travere Therapeutics Inc. Common Stock (TVTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Morgan Stanley vs Travere Therapeutics Inc. Common Stock — how do they compare? Morgan Stanley trades at $182.2 (market cap $293.13B), while Travere Therapeutics Inc. Common Stock trades at $52.74 (market cap $4.88B). The key difference: Morgan Stanley is far larger — about 60.1× Travere Therapeutics Inc. Common Stock's market cap, and Morgan Stanley pays a 2.46% dividend while Travere Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Morgan Stanley for 90 Days and Travere Therapeutics Inc. Common Stock for 0 Days on average.
| MS | TVTX | |
|---|---|---|
Market Cap | $293.13B | $4.88B |
Volume | 8,184,975 | 1,668,577 |
Sector | Financials | Health |
52-Week High | $228.42 | $67.52 |
52-Week Low | $154.37 | $26.79 |
Typical Hold Time | 90 Days | 0 Days |
Enterprise Value | $658.86B | $5.01B |
Dividend Yield | 2.46% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Morgan Stanley (MS) trades at $186.66, down 1.77% on the day, amid a bearish technical signal. The stock shows strong fundamentals with consistent earnings beats, revenue growth from $50.2B in 2022 to $66.0B in 2025, and a net income margin of 27.59%. Analyst consensus is bullish with a $225.50 price target, supported by growth in wealth management and AI financing.
The outlook remains positive given earnings momentum and strategic initiatives, but risks include volatile cash flows, high debt levels, and market sensitivity. Upside potential exists if the company capitalizes on capital markets recovery and AI demand, though investors should monitor leverage and macroeconomic headwinds.
Travere Therapeutics (TVTX) trades at $51.80, down 0.42% on the day, with a neutral technical signal. The company reported strong revenue growth but persistent net losses, with a 2025 net income margin of -7.35%. Recent news includes new data presentations for its key drug FILSPARI and a CEO transition. Analyst consensus is strongly bullish with an 83.33% buy rating and a $70.60 price target, suggesting significant upside from the current price.
The outlook for TVTX hinges on the commercial success of FILSPARI, which shows promising sales growth, but profitability remains a challenge. Key risks include execution of the CEO transition, competitive pressures in nephrology treatments, and the company's ability to achieve sustained profitability. The high valuation multiples relative to negative earnings present a risk-reward balance for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Morgan Stanley
Morgan Stanley is a global investment bank whose history, through its legacy firms, can be traced back to 1924. The company has institutional securities, wealth management, and investment management segments. The company had about $5 trillion of client assets as well as over 70,000 employees at the end of 2021. Approximately 50% of the company's net revenue is from its institutional securities business, with the remainder coming from wealth and investment management. The company derives about 30% of its total revenue outside the Americas.
Read more on MS →About Travere Therapeutics Inc. Common Stock
Travere Therapeutics Inc. is a biopharmaceutical company focused on rare kidney and metabolic diseases. Its lead product, FILSPARI (sparsentan), is an oral medication for adults with IgA nephropathy, and it also markets Thiola for cystinuria.
Read more on TVTX →
